FDAsafety guidance83% confidence
Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Sanofi.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Endocrinology · Type 1 Diabetes
- Sub-indication
- General
Related signal: Trial to Assess Recruitment Methods for Type 1 Diabetes Screening